Foundation Medicine competitors & alternatives

Medical - Diagnostics & Research

Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.

Exact SciencesBiotechGermany

69% match

Similar biotech company

Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.

NeoGenomics, Inc.NEO · BiotechFort Myers, United States

69% matchPublic

Similar biotech company

NeoGenomics, Inc. is a specialized clinical laboratory company headquartered in Fort Myers, Florida. It operates a network of CAP-accredited and CLIA-certified laboratories to provide comprehensive oncology testing and sample processing services.

Similar biotech company

Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).

INTEGRAGENALINT · BiotechFrance

69% matchPublic

Similar biotech company

IntegraGen develops genomic tests, molecular diagnostic products, and bioinformatics software for researchers, clinicians, and biopharma companies. The company specializes in oncology and genetic diseases, offering next-generation sequencing services, data analysis tools, and biomarker identification to support clinical research and diagnostics.

Nexome Genomics Inc.BiotechnologyUnited States

68% matchPrivate

Biotechnology

Nexome Genomics provides cloud-based, integrated analytics solutions that process next-generation sequencing data for healthcare institutions. The company enables hospitals, medical centers, and physician offices to generate on-demand diagnostic and prognostic reports for precision medicine.

Medical - Diagnostics & Research

Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.

Saga Bio, Inc.BiotechnologyUnited States

68% matchPrivate

Biotechnology

SAGA Diagnostics provides ultra-sensitive, blood-based molecular residual disease (MRD) detection and monitoring tests for cancer patients. The company's flagship platform, Pathlight, uses tumor whole-genome sequencing and personalized digital PCR assays to detect circulating tumor DNA, primarily serving clinicians and biopharmaceutical partners for early cancer detection and treatment tracking.

Cofactor GenomicsBiotechUnited States

68% matchPrivate

Similar biotech company

Cofactor Genomics develops RNA-Seq technology and predictive diagnostics to help match cancer patients with appropriate immunotherapy treatments. The company offers tools such as the OncoPrism assay and collaborates with healthcare systems and clinical researchers to evaluate multidimensional biomarkers for various solid tumor cancers.

Predicine Holdings LtdBiotechnology

68% matchPrivate

Biotechnology

Predicine Holdings Ltd provides next-generation liquid biopsy platforms and molecular profiling services for cancer research and precision medicine. The company utilizes proprietary blood- and urine-based assays to analyze circulating tumor DNA and RNA, serving biopharmaceutical partners and clinical researchers in oncology drug development and clinical trials.

LucenceBiotechnologySingapore

67% match

Biotechnology

Lucence is a precision oncology and health diagnostics company that provides ultrasensitive liquid biopsy tests, including cancer screening, treatment selection, and health risk assessment solutions. Using proprietary technologies like AmpliMARK, the company analyzes blood-based genetic material to detect cancer mutations, early-stage malignancies, and cardiovascular risks for patients and healthcare providers.

Biotechnology

Resolution Bioscience is a precision medicine company specializing in cancer diagnostics, DNA sequencing, and liquid biopsy, located in Bellevue, Washington.